NCT00002287已完成不适用
A Placebo-Controlled Trial to Evaluate Retrovir in Preventing Infection With the Human Immunodeficiency Virus (HIV) in Health Care Workers After Accidental Exposure
Glaxo Wellcome2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or blood components.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Exclusion Criteria
- •Co-existing Condition:
- •Patients with the following are excluded:
- •A prior history of a malignancy other than cutaneous basal cell or cervical carcinomas.
- •Other significant, chronic underlying medical illness which, in the physician's judgment, would impair study completion.
- •Evidence of compromised bone marrow function (lab results) with a blood transfusion within the last month.
- •Liver dysfunction as indicated by lab results.
- •Patients are excluded if there is a prior diagnosis of HIV infection by one of the following criteria:
- •HIV antibody positive by ELISA and Western blot assays or by other certified test method. (Patients who are ELISA positive but Western blot or other confirmatory tests are negative may continue in study).
- •HIV antigen positive.
- •Clinical symptoms which lead to a diagnosis by a licensed physician of AIDS or AIDS related complex or AIDS-related dementia. Also excluded are individuals who have experienced similar HIV exposure as described in this protocol in the past month and individuals who have previously been enrolled in this study. The purpose of these exclusions is to eliminate possible seroconversion in an individual that could be attributed to HIV exposure other than the single exposure experienced just prior to entry into the study.
- •Prior Medication:
- •Excluded within 4 weeks of study entry:
- •Any potentially myelosuppressive drug.
- •Nephrotoxic agent.
- •Other experimental therapy.
- •Exposure of a health care worker to HIV-contaminated blood or blood component within 5 days prior to beginning therapy, defined as one of the following:
- •Penetrating wound from needle recently removed from patient or sample container (e.g., blood bag, blood tube) or from sharp object visibly contaminated with HIV-positive blood or blood component. In the case of needlesticks or cuts with sharp objects, blood or blood component must not have been exposed to the air for more than 1 hour. If actual infusion of blood occurs, the 1-hour time limit does not apply.
- •Hypodermic needles should come in contact with the blood and blood component from an HIV source but need not be visibly contaminated with blood to be considered a source of contamination.
- •Significant exposure to HIV-positive blood or blood component as the result of splash on abraded skin.
- •Significant exposure to HIV-positive blood or blood component as the result of splash on mucous membranes.
- •Participant must be able to give informed consent.
- •Active drug or alcohol abuse sufficient in the physician's opinion to prevent compliance with the study regimen.
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular DiseasesAIDS Dementia ComplexNeuromuscular DiseasesHIV InfectionsNCT00002044Glaxo Wellcome
已完成
不适用
A Prospective Double-Blind Study of Retrovir in Early HIV InfectionHIV InfectionsNCT00002045Glaxo Wellcome
已完成
不适用
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)Lymphatic DiseaseHIV InfectionsNCT00002048Glaxo Wellcome
已完成
不适用
The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous SystemHIV InfectionsNCT00002288Glaxo Wellcome
已完成
不适用
Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal FailureHIV InfectionsKidney Failure, ChronicNCT00002047Glaxo Wellcome